Cargando…

Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis

BACKGROUND & AIMS: Prognostic models of cirrhosis underestimate disease severity for patients with cirrhosis and ascites. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein linked to hepatic neoangiogenesis and fibrogenesis. We investigated ascites MFAP4 as a predicto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torp, Nikolaj, Israelsen, Mads, Madsen, Bjørn, Lutz, Philipp, Jansen, Christian, Strassburg, Christian, Mortensen, Christian, Knudsen, Anne Wilkens, Sorensen, Grith Lykke, Holmskov, Uffe, Schlosser, Anders, Thiele, Maja, Trebicka, Jonel, Krag, Aleksander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141937/ https://www.ncbi.nlm.nih.gov/pubmed/34041469 http://dx.doi.org/10.1016/j.jhepr.2021.100287

Ejemplares similares

Corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]
por: Torp, Nikolaj, et al.
Publicado: (2021)

Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
por: Kanaan, Reine, et al.
Publicado: (2023)

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
por: Madsen, Bjørn S., et al.
Publicado: (2020)

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
por: Madsen, Bjørn Stæhr, et al.
Publicado: (2018)

High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal
por: Kjærgaard, Maria, et al.
Publicado: (2017)

Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues: Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular Conditions
por: Wulf-Johansson, Helle, et al.
Publicado: (2013)

Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients
por: Bracht, Thilo, et al.
Publicado: (2016)

Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication
por: Israelsen, Mads, et al.
Publicado: (2021)

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
por: Israelsen, Mads, et al.
Publicado: (2023)

MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis
por: Lutz, Philipp, et al.
Publicado: (2017)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
por: Trebicka, Jonel, et al.
Publicado: (2013)

A Variant Form of the Human Deleted in Malignant Brain Tumor 1 (DMBT1) Gene Shows Increased Expression in Inflammatory Bowel Diseases and Interacts with Dimeric Trefoil Factor 3 (TFF3)
por: Madsen, Jens, et al.
Publicado: (2013)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
por: Mölleken, Christian, et al.
Publicado: (2019)

Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort
por: Sækmose, Susanne Gjørup, et al.
Publicado: (2015)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients
por: Johansson, Sofie Lock, et al.
Publicado: (2019)

MFAP4-Mediated Effects in Elastic Fiber Homeostasis, Integrin Signaling and Cancer, and Its Role in Teleost Fish
por: Mohammadi, Ali, et al.
Publicado: (2022)

Generation of novel trimeric fragments of human SP-A and SP-D after recombinant soluble expression in E. coli
por: Watson, Alastair, et al.
Publicado: (2020)

Peptidoglycan Recognition Peptide 2 Aggravates Weight Loss in a Murine Model of Chemotherapy-Induced Gastrointestinal Toxicity
por: Bech, Ann-Sophie, et al.
Publicado: (2021)

Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis
por: Pilecki, Bartosz, et al.
Publicado: (2018)

MFAP4 Deficiency Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Through Regulation of Macrophage Infiltration and Activity
por: Pilecki, Bartosz, et al.
Publicado: (2021)

Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
por: Meier, Michelle, et al.
Publicado: (2015)

PRO‐C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol‐related liver disease
por: Madsen, Bjørn S., et al.
Publicado: (2021)

Enzyme-Linked Immunosorbent Assay Characterization of Basal Variation and Heritability of Systemic Microfibrillar-Associated Protein 4
por: Sækmose, Susanne Gjørup, et al.
Publicado: (2013)

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension
por: Jansen, Christian, et al.
Publicado: (2014)

Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
por: Rasmussen, Ditlev Nytoft, et al.
Publicado: (2021)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Severe abnormal Heart Rate Turbulence Onset is associated with deterioration of liver cirrhosis
por: Jansen, Christian, et al.
Publicado: (2018)

Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients
por: Riedel, Agnete Nordheim, et al.
Publicado: (2018)

Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series
por: Kimer, Nina, et al.
Publicado: (2020)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

Evolution of nodule stiffness might predict response to local ablative therapy: A series of patients with hepatocellular carcinoma
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway
por: Yao, Li-wen, et al.
Publicado: (2020)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tc1ff3a2f8gqrjacsuqcn2cflf